Last reviewed · How we verify
Sham treatment
Sham treatment is a Small molecule drug developed by RTI International. It is currently FDA-approved for Used as control in clinical research across all therapeutic areas. Also known as: saline, ambient air, 1.2 ATA then changed to 1.0 ATA, Control group.
Sham treatment is a placebo control intervention with no active pharmacological mechanism.
Sham treatment is a placebo control intervention with no active pharmacological mechanism. Used for Used as control in clinical research across all therapeutic areas.
At a glance
| Generic name | Sham treatment |
|---|---|
| Also known as | saline, ambient air, 1.2 ATA then changed to 1.0 ATA, Control group, Saline solution and general anesthesia |
| Sponsor | RTI International |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Sham treatment refers to an inert or inactive intervention used as a control in clinical trials and research studies. It is designed to mimic the appearance and administration of an active treatment while containing no therapeutic agent, allowing researchers to isolate the true effect of an investigational drug from placebo effects.
Approved indications
- Used as control in clinical research across all therapeutic areas
Common side effects
- Placebo effect (perceived symptom improvement without active agent)
Key clinical trials
- Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease (NA)
- Wild Blueberries for Gut, Brain, and Heart Health in Adults With High Blood Pressure (NA)
- The Effects of Resistance Training and a Plant-Based Supplement on Perimenopausal Symptoms and Muscle Health. (NA)
- A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP) (PHASE2)
- Phase I Trial of High-Density Theta Burst Stimulation (hdTBS) (PHASE1)
- A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases (PHASE3)
- EFFECT OF ANODAL TRANSCRANIAL DIRECT CURRENT STIMULATION ON NAMING IN APHASIC PATIENTS WITH ACUTE ISCHEMIC STROKE (PHASE3)
- Trial of Suvorexant for Sleep in Children With Autism (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sham treatment CI brief — competitive landscape report
- Sham treatment updates RSS · CI watch RSS
- RTI International portfolio CI
Frequently asked questions about Sham treatment
What is Sham treatment?
How does Sham treatment work?
What is Sham treatment used for?
Who makes Sham treatment?
Is Sham treatment also known as anything else?
What development phase is Sham treatment in?
What are the side effects of Sham treatment?
Related
- Manufacturer: RTI International — full pipeline
- Indication: Drugs for Used as control in clinical research across all therapeutic areas
- Also known as: saline, ambient air, 1.2 ATA then changed to 1.0 ATA, Control group, Saline solution and general anesthesia
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing